155 related articles for article (PubMed ID: 32379896)
21. Functional and druggability analysis of the SARS-CoV-2 proteome.
Cavasotto CN; Lamas MS; Maggini J
Eur J Pharmacol; 2021 Jan; 890():173705. PubMed ID: 33137330
[TBL] [Abstract][Full Text] [Related]
22. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
23. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
Cao R; Hu H; Li Y; Wang X; Xu M; Liu J; Zhang H; Yan Y; Zhao L; Li W; Zhang T; Xiao D; Guo X; Li Y; Yang J; Hu Z; Wang M; Zhong W
ACS Infect Dis; 2020 Sep; 6(9):2524-2531. PubMed ID: 32786284
[TBL] [Abstract][Full Text] [Related]
24. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.
Maurya SK; Maurya AK; Mishra N; Siddique HR
J Recept Signal Transduct Res; 2020 Dec; 40(6):605-612. PubMed ID: 32476594
[TBL] [Abstract][Full Text] [Related]
25. Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2.
Martin WR; Cheng F
J Proteome Res; 2020 Nov; 19(11):4670-4677. PubMed ID: 32907334
[TBL] [Abstract][Full Text] [Related]
26. Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease.
Menéndez CA; Byléhn F; Perez-Lemus GR; Alvarado W; de Pablo JJ
Sci Adv; 2020 Sep; 6(37):. PubMed ID: 32917717
[TBL] [Abstract][Full Text] [Related]
27. Structural Insights into the Binding Modes of Viral RNA-Dependent RNA Polymerases Using a Function-Site Interaction Fingerprint Method for RNA Virus Drug Discovery.
Zhao Z; Bourne PE
J Proteome Res; 2020 Nov; 19(11):4698-4705. PubMed ID: 32946692
[TBL] [Abstract][Full Text] [Related]
28. Understanding COVID-19 via comparative analysis of dark proteomes of SARS-CoV-2, human SARS and bat SARS-like coronaviruses.
Giri R; Bhardwaj T; Shegane M; Gehi BR; Kumar P; Gadhave K; Oldfield CJ; Uversky VN
Cell Mol Life Sci; 2021 Feb; 78(4):1655-1688. PubMed ID: 32712910
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 RNA polymerase as target for antiviral therapy.
Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM
J Transl Med; 2020 May; 18(1):185. PubMed ID: 32370758
[TBL] [Abstract][Full Text] [Related]
30. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.
Meyer-Almes FJ
Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050
[TBL] [Abstract][Full Text] [Related]
31.
Gurung AB
Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
[TBL] [Abstract][Full Text] [Related]
32. Structure of M
Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H
Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481
[TBL] [Abstract][Full Text] [Related]
33. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov.
Zhang H; Saravanan KM; Yang Y; Hossain MT; Li J; Ren X; Pan Y; Wei Y
Interdiscip Sci; 2020 Sep; 12(3):368-376. PubMed ID: 32488835
[TBL] [Abstract][Full Text] [Related]
34. Repurposing Low-Molecular-Weight Drugs against the Main Protease of Severe Acute Respiratory Syndrome Coronavirus 2.
Gao J; Zhang L; Liu X; Li F; Ma R; Zhu Z; Zhang J; Wu J; Shi Y; Pan Y; Ge Y; Ruan K
J Phys Chem Lett; 2020 Sep; 11(17):7267-7272. PubMed ID: 32787337
[TBL] [Abstract][Full Text] [Related]
35. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
[TBL] [Abstract][Full Text] [Related]
36. The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies.
Waman VP; Sen N; Varadi M; Daina A; Wodak SJ; Zoete V; Velankar S; Orengo C
Brief Bioinform; 2021 Mar; 22(2):742-768. PubMed ID: 33348379
[TBL] [Abstract][Full Text] [Related]
37. Mechanistic-Based Classification of Endocytosis-Related Inhibitors: Does It Aid in Assigning Drugs against SARS-CoV-2?
Hessien M; Donia T; Tabll AA; Adly E; Abdelhafez TH; Attia A; Alkafaas SS; Kuna L; Glasnovic M; Cosic V; Smolic R; Smolic M
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243127
[TBL] [Abstract][Full Text] [Related]
38. Exploring the effectiveness of the TSR-based protein 3-D structural comparison method for protein clustering, and structural motif identification and discovery of protein kinases, hydrolases, and SARS-CoV-2's protein via the application of amino acid grouping.
Sarkar T; Raghavan VV; Chen F; Riley A; Zhou S; Xu W
Comput Biol Chem; 2021 Jun; 92():107479. PubMed ID: 33951604
[TBL] [Abstract][Full Text] [Related]
39. Genomics approaches to synthesize plant-based biomolecules for therapeutic applications to combat SARS-CoV-2.
Sharma N; Muthamilarasan M; Prasad A; Prasad M
Genomics; 2020 Nov; 112(6):4322-4331. PubMed ID: 32717321
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the Antiviral Potential of Modified Heterocyclic Base and 5'-Norcarbocyclic Nucleoside Analogs Against SARS-CoV-2.
Matyugina ES; Novikov MS; Kozlovskaya LI; Volok VP; Shustova EY; Ishmukhametov AA; Kochetkov SN; Khandazhinskaya AL
Acta Naturae; 2021; 13(4):78-81. PubMed ID: 35127150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
